分泌性中耳炎病因分类精准治疗的临床研究

注册号:

Registration number:

ChiCTR2300076404 

最近更新日期:

Date of Last Refreshed on:

2024-03-15 19:02:39 

注册时间:

Date of Registration:

2023-10-08 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

分泌性中耳炎病因分类精准治疗的临床研究

Public title:

Clinical trial on precise treatment of secretory otitis media according to etiology classification

注册题目简写:

English Acronym:

研究课题的正式科学名称:

分泌性中耳炎病因分类精准治疗的临床研究

Scientific title:

Clinical trial on precise treatment of secretory otitis media according to etiology classification

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

廖志芳 

研究负责人:

廖志芳 

Applicant:

Liao Zhifang 

Study leader:

Liao Zhifang 

申请注册联系人电话:

Applicant telephone:

+86 137 9856 6543

研究负责人电话:

Study leader's
telephone:

+86 137 9856 6543

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

260930229@qq.com

研究负责人电子邮件:

Study leader's E-mail:

260930229@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省深圳市罗湖区东门北路1017号

研究负责人通讯地址:

广东省深圳市罗湖区东门北路1017号

Applicant address:

1017 Dongmen Road North, Luohu District, Shenzhen, Guangdong, China

Study leader's address:

1017 Dongmen Road North, Luohu District, Shenzhen, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

深圳市人民医院

Applicant's institution:

The Second Clinical Medical College

研究负责人所在单位:

深圳市人民医院

Affiliation of the Leader:

The Second Clinical Medical College

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY- LL-2020257

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

深圳市人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Shenzhen People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2020-04-28 00:00:00

伦理委员会联系人:

骆瑜

Contact Name of the ethic committee:

Luo Yu

伦理委员会联系地址:

广东省深圳市罗湖区东门北路1017号

Contact Address of the ethic committee:

1017 Dongmen Road North, Luohu District, Shenzhen, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 186 8224 2616

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

深圳市人民医院

Primary sponsor:

The Second Clinical Medical College

研究实施负责(组长)单位地址:

广东省深圳市罗湖区东门北路1017号

Primary sponsor's address:

1017 Dongmen Road North, Luohu District, Shenzhen, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

深圳市人民医院

具体地址:

广东省深圳市罗湖区东门北路1017号

Institution
hospital:

Shenzhen People's Hospital

Address:

1017 Dongmen Road North, Luohu District, Shenzhen, Guangdong, China

经费或物资来源:

导师资助

Source(s) of funding:

Tutor support

研究疾病:

分泌性中耳炎  

Target disease:

Secretory otitis media

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

依据分泌性中耳炎相关病因分类进行精准治疗的研究,指导临床,为分泌性中耳炎的防治研究提供新的线索及理论依据。  

Objectives of Study:

According to the related etiology classification of secretory otitis media, precise treatment research is conducted to guide clinical practice and provide new clues and theoretical basis for the prevention and treatment of secretory otitis media.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.化脓性中耳炎; 2.鼓膜穿孔; 3.肿瘤; 4.严重的系统性疾病; 5.失访的患者; 6.对大环内酯类药物、质子泵抑制剂药物不耐受或过敏者。

Exclusion criteria:

1. Suppurative otitis media; 2. Tympanic membrane perforation; 3. Patients with tumors; 4. Severe systemic diseases; 5. Patients who were lost to follow-up; 6. People who are intolerant macrolides or proton pump inhibitors of drug or allergic.

研究实施时间:

Study execute time:

From 2020-07-01 00:00:00 To 2023-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-07-01 00:00:00 To 2023-12-31 00:00:00

干预措施:

Interventions:

组别:

腺样体肥大

样本量:

30

Group:

Adenoidal hypertrophy

Sample size:

干预措施:

药物按成人分类给药

干预措施代码:

Intervention:

Drugs are classified by adults

Intervention code:

组别:

急性感染

样本量:

30

Group:

Acute infection

Sample size:

干预措施:

大环内酯类药物,桉柠蒎

干预措施代码:

Intervention:

Macrolides of drug, limonene and pinene enteric capsules

Intervention code:

组别:

鼻窦炎

样本量:

30

Group:

Nasosinusitis

Sample size:

干预措施:

大环内酯类、桉柠蒎、鼻用激素、

干预措施代码:

Intervention:

Macrolides of drug, limonene and pinene enteric capsules, intranasal corticosteroids

Intervention code:

组别:

胃食管返流

样本量:

15

Group:

Gastroesophageal reflux

Sample size:

干预措施:

桉柠蒎、质子泵抑制剂

干预措施代码:

Intervention:

Limonene and pinene enteric capsules, proton pump inhibitors of drug

Intervention code:

组别:

鼻炎

样本量:

15

Group:

Rhinitis

Sample size:

干预措施:

鼻用激素、桉柠蒎

干预措施代码:

Intervention:

Intranasal corticosteroids, limonene and pinene enteric capsules

Intervention code:

组别:

变应性鼻炎或变应性疾病

样本量:

30

Group:

Allergic rhinitis or allergic diseases

Sample size:

干预措施:

抗组胺药、鼻用激素、桉柠蒎

干预措施代码:

Intervention:

Antihistamine drug, intranasal corticosteroids, limonene and pinene enteric capsules

Intervention code:

组别:

对照组

样本量:

150

Group:

Control group

Sample size:

干预措施:

口服激素、桉柠蒎

干预措施代码:

Intervention:

Oral hormones, limonene and pinene enteric capsules

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

深圳市 

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

深圳市人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shenzhen People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

声导抗

指标类型:

主要指标

Outcome:

Tympanogram

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

炎症因子

指标类型:

次要指标

Outcome:

Inflammatory factor

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

鼓膜检查

指标类型:

主要指标

Outcome:

Tympanic membrane examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

详细病史

指标类型:

次要指标

Outcome:

Detailed medical history

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

鼻咽部组织、鼻息肉

组织:

Sample Name:

Nasopharyngeal tissue and nasal polyps

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

中耳积液

组织:

Sample Name:

Middle ear effusion

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 2 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Resman

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Resman

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-10-08 10:00:34